Phase 3 Granulomatosis With Polyangiitis Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Eosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilia Syndrome (HES)
AstraZeneca14 enrolled15 locationsNCT06512883
Recruiting
Phase 3
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatosis With Polyangiitis
Assistance Publique - Hôpitaux de Paris42 enrolled1 locationNCT04871191
Recruiting
Phase 3
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
Granulomatosis With PolyangiitisMicroscopic Polyangiitis (MPA)
Ottawa Hospital Research Institute36 enrolled2 locationsNCT06983821
Recruiting
Phase 2Phase 3
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
Eosinophilic Granulomatosis With Polyangiitis
Guangdong Hengrui Pharmaceutical Co., Ltd166 enrolled2 locationsNCT05979051